rs2289404
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_016467.5(ORMDL1):c.*479C>T variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.435 in 82,548 control chromosomes in the GnomAD database, including 4,566 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.44 ( 4564 hom., cov: 33)
Exomes 𝑓: 0.23 ( 2 hom. )
Consequence
ORMDL1
NM_016467.5 3_prime_UTR
NM_016467.5 3_prime_UTR
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: 0.339
Publications
12 publications found
Genes affected
ORMDL1 (HGNC:16036): (ORMDL sphingolipid biosynthesis regulator 1) Involved in ceramide metabolic process. Acts upstream of or within negative regulation of ceramide biosynthetic process. Located in endoplasmic reticulum membrane. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.86).
BA1
GnomAd4 highest subpopulation (AMR) allele frequency at 95% confidence interval = 0.475 is higher than 0.05.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.436 AC: 35875AN: 82328Hom.: 4553 Cov.: 33 show subpopulations
GnomAD3 genomes
AF:
AC:
35875
AN:
82328
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.234 AC: 30AN: 128Hom.: 2 Cov.: 0 AF XY: 0.231 AC XY: 18AN XY: 78 show subpopulations
GnomAD4 exome
AF:
AC:
30
AN:
128
Hom.:
Cov.:
0
AF XY:
AC XY:
18
AN XY:
78
show subpopulations
African (AFR)
AF:
AC:
2
AN:
2
American (AMR)
AF:
AC:
4
AN:
10
Ashkenazi Jewish (ASJ)
AF:
AC:
1
AN:
2
East Asian (EAS)
AF:
AC:
0
AN:
4
South Asian (SAS)
AF:
AC:
0
AN:
10
European-Finnish (FIN)
AF:
AC:
0
AN:
2
Middle Eastern (MID)
AC:
0
AN:
0
European-Non Finnish (NFE)
AF:
AC:
20
AN:
88
Other (OTH)
AF:
AC:
3
AN:
10
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.481
Heterozygous variant carriers
0
1
2
4
5
6
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.436 AC: 35913AN: 82420Hom.: 4564 Cov.: 33 AF XY: 0.436 AC XY: 17340AN XY: 39746 show subpopulations
GnomAD4 genome
AF:
AC:
35913
AN:
82420
Hom.:
Cov.:
33
AF XY:
AC XY:
17340
AN XY:
39746
show subpopulations
African (AFR)
AF:
AC:
13415
AN:
28378
American (AMR)
AF:
AC:
3874
AN:
7942
Ashkenazi Jewish (ASJ)
AF:
AC:
741
AN:
1858
East Asian (EAS)
AF:
AC:
1173
AN:
2682
South Asian (SAS)
AF:
AC:
580
AN:
1486
European-Finnish (FIN)
AF:
AC:
2061
AN:
4492
Middle Eastern (MID)
AF:
AC:
75
AN:
166
European-Non Finnish (NFE)
AF:
AC:
13397
AN:
33946
Other (OTH)
AF:
AC:
473
AN:
1060
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
1416
2832
4249
5665
7081
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
368
736
1104
1472
1840
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
705
AN:
3470
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.